Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap ...

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust

And can Novo Nordisk catch up to its rival in the weight loss market?

More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.
AOL

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Eli Lilly's weight loss medicine, Zepbound, and Novo Nordisk's Wegovy have gone head-to-head in a clinical trial. The former emerged victorious, leading to a mean weight loss of 20.2% compared ...
24/7 Wall St. on MSN

Fast Money panel says Novo Nordisk now more compelling than Eli Lilly after falling 70%

Quick Read CNBC’s Fast Money panel argues Novo Nordisk (NVO) now offers better value than Eli Lilly (LLY) after NVO’s 68% ...
Devdiscourse

Eli Lilly's Foundayo: Investors Seek Clarity Amid Promising Launch

Eli Lilly investors are eagerly anticipating insights regarding Foundayo, the newly launched weight-loss pill. Despite ...

Eli Lilly Sales Surge 56% as Booming GLP-1 Demand Eclipses Lower Prices

The results were driven by a 65% jump in volume amid a booming demand for weight-loss drugs like Lilly’s Mounjaro and ...